Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.

Isaacsson Velho P, Fu W, Wang H, Mirkheshti N, Qazi F, Lima FAS, Shaukat F, Carducci MA, Denmeade SR, Paller CJ, Markowski MC, Marshall CH, Eisenberger MA, Antonarakis ES.

Eur Urol. 2019 Jun 5. pii: S0302-2838(19)30439-7. doi: 10.1016/j.eururo.2019.05.032. [Epub ahead of print]

PMID:
31176623
2.

Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT.

Meyer AR, Carducci MA, Denmeade SR, Markowski MC, Pomper MG, Pierorazio PM, Allaf ME, Rowe SP, Gorin MA.

Ann Nucl Med. 2019 May 30. doi: 10.1007/s12149-019-01371-8. [Epub ahead of print]

PMID:
31147927
3.

Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer.

Torquato S, Pallavajjala A, Goldstein A, Toro PV, Silberstein JL, Lee J, Nakazawa M, Waters I, Chu D, Shinn D, Groginski T, Hughes RM, Simons BW, Khan H, Feng Z, Carducci MA, Paller CJ, Denmeade SR, Kressel B, Eisenberger MA, Antonarakis ES, Trock BJ, Park BH, Hurley PJ.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00227. Epub 2019 Apr 3.

4.

Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU-AA-302.

Teply BA, Qiu F, Antonarakis ES, Carducci MA, Denmeade SR.

Prostate. 2019 Jun;79(8):929-933. doi: 10.1002/pros.23798.

PMID:
31059588
5.

In Reply to the Letter to the Editor from Raj et al.: Clinical Evidence Indicates Allogeneic Mesenchymal Stem Cells Do Not Pose a Significant Risk for Cancer Progression in the Context of Cell-Based Drug Delivery.

Brennen WN, Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Denmeade SR.

Stem Cells Transl Med. 2019 Mar 29. doi: 10.1002/sctm.19-0068. [Epub ahead of print] No abstract available.

6.

Albumin-linked prostate-specific antigen-activated thapsigargin- and niclosamide-based molecular grenades targeting the microenvironment in metastatic castration-resistant prostate cancer.

Akinboye ES, Brennen WN, Denmeade SR, Isaacs JT.

Asian J Urol. 2019 Jan;6(1):99-108. doi: 10.1016/j.ajur.2018.11.004. Epub 2018 Nov 28. Review.

7.

A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer.

Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Brennen WN, Denmeade SR.

Stem Cells Transl Med. 2019 May;8(5):441-449. doi: 10.1002/sctm.18-0230. Epub 2019 Feb 8.

8.

Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.

Isaacsson Velho P, Qazi F, Hassan S, Carducci MA, Denmeade SR, Markowski MC, Thorek DL, DeWeese TL, Song DY, Tran PT, Eisenberger MA, Antonarakis ES.

Eur Urol. 2018 Oct 4. pii: S0302-2838(18)30729-2. doi: 10.1016/j.eururo.2018.09.040. [Epub ahead of print]

PMID:
30293905
9.

Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise.

Krueger TEG, Thorek DLJ, Denmeade SR, Isaacs JT, Brennen WN.

Stem Cells Transl Med. 2018 Sep;7(9):651-663. doi: 10.1002/sctm.18-0024. Epub 2018 Aug 1. Review.

10.

Bipolar androgen therapy in the treatment of prostate cancer.

Denmeade SR.

Clin Adv Hematol Oncol. 2018 Jun;16(6):408-411. No abstract available.

PMID:
30067610
11.

PSA-selective activation of cytotoxic human serine proteases within the tumor microenvironment as a therapeutic strategy to target prostate cancer.

Rogers OC, Anthony L, Rosen DM, Brennen WN, Denmeade SR.

Oncotarget. 2018 Apr 27;9(32):22436-22450. doi: 10.18632/oncotarget.25091. eCollection 2018 Apr 27.

12.

PSA-alpha-2-macroglobulin complex is enzymatically active in the serum of patients with advanced prostate cancer and can degrade circulating peptide hormones.

Kostova MB, Brennen WN, Lopez D, Anthony L, Wang H, Platz E, Denmeade SR.

Prostate. 2018 Aug;78(11):819-829. doi: 10.1002/pros.23539. Epub 2018 Apr 16.

PMID:
29659051
13.

Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.

Teply BA, Wang H, Luber B, Sullivan R, Rifkind I, Bruns A, Spitz A, DeCarli M, Sinibaldi V, Pratz CF, Lu C, Silberstein JL, Luo J, Schweizer MT, Drake CG, Carducci MA, Paller CJ, Antonarakis ES, Eisenberger MA, Denmeade SR.

Lancet Oncol. 2018 Jan;19(1):76-86. doi: 10.1016/S1470-2045(17)30906-3. Epub 2017 Dec 14.

14.

Anticancer activities of emetine prodrugs that are proteolytically activated by the prostate specific antigen (PSA) and evaluation of in vivo toxicity of emetine derivatives.

Akinboye ES, Rosen MD, Bakare O, Denmeade SR.

Bioorg Med Chem. 2017 Dec 15;25(24):6707-6717. doi: 10.1016/j.bmc.2017.11.015. Epub 2017 Nov 10.

15.

Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial.

Paller CJ, Zhou XC, Heath EI, Taplin ME, Mayer T, Stein MN, Bubley GJ, Pili R, Hudson T, Kakarla R, Abbas MM, Anders NM, Dowling D, King S, Bruns AB, Wagner WD, Drake CG, Antonarakis ES, Eisenberger MA, Denmeade SR, Rudek MA, Rosner GL, Carducci MA.

Clin Cancer Res. 2018 Jan 15;24(2):306-315. doi: 10.1158/1078-0432.CCR-17-1100. Epub 2017 Nov 7.

16.

Rationale for bipolar androgen therapy (BAT) for metastatic prostate cancer.

Isaacs JT, Brennen WN, Denmeade SR.

Cell Cycle. 2017 Sep 17;16(18):1639-1640. doi: 10.1080/15384101.2017.1360645. Epub 2017 Aug 18. No abstract available.

17.

Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate.

Brennen WN, Zhang B, Kulac I, Kisteman LN, Antony L, Wang H, Meeker AK, De Marzo AM, Garraway IP, Denmeade SR, Isaacs JT.

Oncotarget. 2017 Jul 18;8(29):46710-46727. doi: 10.18632/oncotarget.17362.

18.

Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.

Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Zhu Y, Silberstein JL, Taylor MN, Maughan BL, Denmeade SR, Pienta KJ, Paller CJ, Carducci MA, Eisenberger MA, Luo J.

J Clin Oncol. 2017 Jul 1;35(19):2149-2156. doi: 10.1200/JCO.2016.70.1961. Epub 2017 Apr 6.

19.

Bipolar Androgen Therapy: A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer.

Schweizer MT, Antonarakis ES, Denmeade SR.

Eur Urol. 2017 Sep;72(3):323-325. doi: 10.1016/j.eururo.2017.03.022. Epub 2017 Mar 29.

20.

Clinical Applications of Molecular Imaging in the Management of Prostate Cancer.

Gorin MA, Rowe SP, Denmeade SR.

PET Clin. 2017 Apr;12(2):185-192. doi: 10.1016/j.cpet.2016.11.001. Epub 2017 Jan 16. Review.

PMID:
28267452
21.

Androgen Receptor Splice Variants Are Not Substrates of Nonsense-Mediated Decay.

Ajiboye AS, Esopi D, Yegnasubramanian S, Denmeade SR.

Prostate. 2017 Jun;77(8):829-837. doi: 10.1002/pros.23323. Epub 2017 Feb 22.

22.

Detection fidelity of AR mutations in plasma derived cell-free DNA.

Goldstein A, Toro PV, Lee J, Silberstein JL, Nakazawa M, Waters I, Cravero K, Chu D, Cochran RL, Kim M, Shinn D, Torquato S, Hughes RM, Pallavajjala A, Carducci MA, Paller CJ, Denmeade SR, Kressel B, Trock BJ, Eisenberger MA, Antonarakis ES, Park BH, Hurley PJ.

Oncotarget. 2017 Feb 28;8(9):15651-15662. doi: 10.18632/oncotarget.14926.

23.

Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.

Na R, Zheng SL, Han M, Yu H, Jiang D, Shah S, Ewing CM, Zhang L, Novakovic K, Petkewicz J, Gulukota K, Helseth DL Jr, Quinn M, Humphries E, Wiley KE, Isaacs SD, Wu Y, Liu X, Zhang N, Wang CH, Khandekar J, Hulick PJ, Shevrin DH, Cooney KA, Shen Z, Partin AW, Carter HB, Carducci MA, Eisenberger MA, Denmeade SR, McGuire M, Walsh PC, Helfand BT, Brendler CB, Ding Q, Xu J, Isaacs WB.

Eur Urol. 2017 May;71(5):740-747. doi: 10.1016/j.eururo.2016.11.033. Epub 2016 Dec 15.

24.

Extreme Response to High-dose Testosterone in BRCA2- and ATM-mutated Prostate Cancer.

Teply BA, Kachhap S, Eisenberger MA, Denmeade SR.

Eur Urol. 2017 Mar;71(3):499. doi: 10.1016/j.eururo.2016.09.020. Epub 2016 Sep 29. No abstract available.

25.

Challenges of conducting clinical trials of natural products to combat cancer.

Paller CJ, Denmeade SR, Carducci MA.

Clin Adv Hematol Oncol. 2016 Jun;14(6):447-55. Review.

PMID:
27379814
26.

Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study.

Schweizer MT, Wang H, Luber B, Nadal R, Spitz A, Rosen DM, Cao H, Antonarakis ES, Eisenberger MA, Carducci MA, Paller C, Denmeade SR.

Prostate. 2016 Sep;76(13):1218-26. doi: 10.1002/pros.23209. Epub 2016 Jun 24.

PMID:
27338150
27.

Mutational Analysis of Prostate-Specific Antigen Defines the Intrinsic Proteolytic Activity of the proPSA Zymogen.

Sangster-Guity N, Tu-Sekine B, Raben DM, Denmeade SR, Williams SA.

Prostate. 2016 Sep;76(13):1203-17. doi: 10.1002/pros.23216. Epub 2016 Jun 8.

PMID:
27273171
28.

A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer.

Levy O, Brennen WN, Han E, Rosen DM, Musabeyezu J, Safaee H, Ranganath S, Ngai J, Heinelt M, Milton Y, Wang H, Bhagchandani SH, Joshi N, Bhowmick N, Denmeade SR, Isaacs JT, Karp JM.

Biomaterials. 2016 Jun;91:140-150. doi: 10.1016/j.biomaterials.2016.03.023. Epub 2016 Mar 17.

29.

The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer.

Teply BA, Luber B, Denmeade SR, Antonarakis ES.

Prostate Cancer Prostatic Dis. 2016 Mar;19(1):72-8. doi: 10.1038/pcan.2015.53. Epub 2015 Nov 17.

30.

Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy.

Akinboye ES, Brennen WN, Rosen DM, Bakare O, Denmeade SR.

Prostate. 2016 Jun;76(8):703-14. doi: 10.1002/pros.23162. Epub 2016 Feb 2.

31.

Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies.

Nadal R, Tsai HL, Sinibaldi VJ, Paller CJ, Antonarakis ES, Denmeade SR, Carducci MA, Eisenberger MA.

Prostate. 2016 Apr;76(5):512-20. doi: 10.1002/pros.23141. Epub 2015 Dec 22.

PMID:
26689606
32.

Design, synthesis and cytotoxicity studies of dithiocarbamate ester derivatives of emetine in prostate cancer cell lines.

Akinboye ES, Bamji ZD, Kwabi-Addo B, Ejeh D, Copeland RL, Denmeade SR, Bakare O.

Bioorg Med Chem. 2015 Sep 1;23(17):5839-45. doi: 10.1016/j.bmc.2015.06.072. Epub 2015 Jul 4.

33.

Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.

Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J.

JAMA Oncol. 2015 Aug;1(5):582-91. doi: 10.1001/jamaoncol.2015.1341.

34.

A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination.

Paller CJ, Rudek MA, Zhou XC, Wagner WD, Hudson TS, Anders N, Hammers HJ, Dowling D, King S, Antonarakis ES, Drake CG, Eisenberger MA, Denmeade SR, Rosner GL, Carducci MA.

Prostate. 2015 Oct;75(14):1518-25. doi: 10.1002/pros.23024. Epub 2015 May 27.

35.

CCAAT/Enhancer binding protein β controls androgen-deprivation-induced senescence in prostate cancer cells.

Barakat DJ, Zhang J, Barberi T, Denmeade SR, Friedman AD, Paz-Priel I.

Oncogene. 2015 Nov 26;34(48):5912-22. doi: 10.1038/onc.2015.41. Epub 2015 Mar 16.

36.

Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.

Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, Luo J, Haffner MC, Yegnasubramanian S, Carducci MA, Eisenberger MA, Isaacs JT, Denmeade SR.

Sci Transl Med. 2015 Jan 7;7(269):269ra2. doi: 10.1126/scitranslmed.3010563.

37.

Protease-activated pore-forming peptides for the treatment and imaging of prostate cancer.

LeBeau AM, Denmeade SR.

Mol Cancer Ther. 2015 Mar;14(3):659-68. doi: 10.1158/1535-7163.MCT-14-0744. Epub 2014 Dec 23.

38.

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J.

N Engl J Med. 2014 Sep 11;371(11):1028-38. doi: 10.1056/NEJMoa1315815. Epub 2014 Sep 3.

39.

Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.

Nadal R, Zhang Z, Rahman H, Schweizer MT, Denmeade SR, Paller CJ, Carducci MA, Eisenberger MA, Antonarakis ES.

Prostate. 2014 Nov;74(15):1560-8. doi: 10.1002/pros.22874. Epub 2014 Aug 31.

40.

Targeting thapsigargin towards tumors.

Doan NT, Paulsen ES, Sehgal P, Møller JV, Nissen P, Denmeade SR, Isaacs JT, Dionne CA, Christensen SB.

Steroids. 2015 May;97:2-7. doi: 10.1016/j.steroids.2014.07.009. Epub 2014 Jul 24. Review.

41.

Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer.

Brennen WN, Rosen DM, Chaux A, Netto GJ, Isaacs JT, Denmeade SR.

Prostate. 2014 Sep;74(13):1308-19. doi: 10.1002/pros.22847. Epub 2014 Jul 22.

42.

The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer.

Paller CJ, Olatoye D, Xie S, Zhou X, Denmeade SR, Eisenberger MA, Antonarakis ES, Carducci MA, Rosner GL.

Prostate Cancer Prostatic Dis. 2014 Mar;17(1):28-33. doi: 10.1038/pcan.2013.40. Epub 2013 Oct 8.

43.

Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment.

Brennen WN, Denmeade SR, Isaacs JT.

Endocr Relat Cancer. 2013 Aug 23;20(5):R269-90. doi: 10.1530/ERC-13-0151. Print 2013 Oct. Review.

44.

Structural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitors.

Kostova MB, Rosen DM, Chen Y, Mease RC, Denmeade SR.

J Med Chem. 2013 Jun 13;56(11):4224-35. doi: 10.1021/jm301718c. Epub 2013 Jun 4.

45.

Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation.

Wang GM, Wong HY, Konishi H, Blair BG, Abukhdeir AM, Gustin JP, Rosen DM, Denmeade SR, Rasheed Z, Matsui W, Garay JP, Mohseni M, Higgins MJ, Cidado J, Jelovac D, Croessmann S, Cochran RL, Karnan S, Konishi Y, Ota A, Hosokawa Y, Argani P, Lauring J, Park BH.

Cancer Res. 2013 Jun 1;73(11):3248-61. doi: 10.1158/0008-5472.CAN-12-1578. Epub 2013 Apr 11.

46.

Proteolysis of complement factors iC3b and C5 by the serine protease prostate-specific antigen in prostatic fluid and seminal plasma.

Manning ML, Williams SA, Jelinek CA, Kostova MB, Denmeade SR.

J Immunol. 2013 Mar 15;190(6):2567-74. doi: 10.4049/jimmunol.1200856. Epub 2013 Feb 11.

47.

Quantification of Mesenchymal Stem Cells (MSCs) at sites of human prostate cancer.

Brennen WN, Chen S, Denmeade SR, Isaacs JT.

Oncotarget. 2013 Jan;4(1):106-17.

48.

Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia.

Elhilali MM, Pommerville P, Yocum RC, Merchant R, Roehrborn CG, Denmeade SR.

J Urol. 2013 Apr;189(4):1421-6. doi: 10.1016/j.juro.2012.11.003. Epub 2012 Nov 7.

49.

The unfolding treatment landscape for men with castration-resistant prostate cancer.

Kim JJ, Keizman D, Denmeade SR, Antonarakis ES.

Clin Investig (Lond). 2011 Nov;1(11):1533-1544.

50.

Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug.

Brennen WN, Rosen DM, Wang H, Isaacs JT, Denmeade SR.

J Natl Cancer Inst. 2012 Sep 5;104(17):1320-34. doi: 10.1093/jnci/djs336. Epub 2012 Aug 21.

Supplemental Content

Loading ...
Support Center